29
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Analysis of Past and Present Synthetic Methodologies on Medicinal Chemistry: Where Have All the New Reactions Gone? : Miniperspective

      1 , 2
      Journal of Medicinal Chemistry
      American Chemical Society (ACS)

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          An analysis of chemical reactions used in current medicinal chemistry (2014), three decades ago (1984), and in natural product total synthesis has been conducted. The analysis revealed that of the current most frequently used synthetic reactions, none were discovered within the past 20 years and only two in the 1980s and 1990s (Suzuki-Miyaura and Buchwald-Hartwig). This suggests an inherent high bar of impact for new synthetic reactions in drug discovery. The most frequently used reactions were amide bond formation, Suzuki-Miyaura coupling, and SNAr reactions, most likely due to commercial availability of reagents, high chemoselectivity, and a pressure on delivery. We show that these practices result in overpopulation of certain types of molecular shapes to the exclusion of others using simple PMI plots. We hope that these results will help catalyze improvements in integration of new synthetic methodologies as well as new library design.

          Related collections

          Author and article information

          Journal
          Journal of Medicinal Chemistry
          J. Med. Chem.
          American Chemical Society (ACS)
          0022-2623
          1520-4804
          May 26 2016
          May 26 2016
          December 2015
          May 26 2016
          : 59
          : 10
          : 4443-4458
          Affiliations
          [1 ]AstraZeneca Neurosciences, IMED Biotech Unit, AstraZeneca R&D Boston, 141 Portland Street, Cambridge, Massachusetts 02139, United States
          [2 ]CVMD Innovative Medicines, IMED Biotech Unit, AstraZeneca, Mölndal SE-431 83, Sweden
          Article
          10.1021/acs.jmedchem.5b01409
          26571338
          47704ff3-566d-4b43-a3b1-e7f3a9bec261
          © 2016

          http://pubs.acs.org/page/policy/authorchoice_termsofuse.html

          History

          Comments

          Comment on this article